Medytox Selects IQVIA’s Enterprise Quality Management Platform, Including SmartSolve®, for Quality and Compliance Management
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE: IQV) today announced that the global biopharmaceutical company Medytox has selected IQVIA’s Enterprise Quality Management Solutions (EQMS) platform for quality and compliance management. The platform uniquely supports Medytox’s goals of meeting industry regulatory requirements and exceeding global quality standards.
IQVIA’s EQMS platform includes the market-leading SmartSolve® application and an integrated suite of quality, regulatory, market surveillance, and safety compliance solutions. It provides clients with the first-of-its-kind end-to-end, “molecule-to-market” approach for life science companies to coordinate their management of varied, constantly changing global requirements.
“We selected IQVIA because we wanted a proven, effective, e-system approach that adheres to current Good Manufacturing Practices to manage our quality management processes across our network of manufacturing plants within Korea,” said Michael Lopez, senior vice president of Global Quality for Medytox. “We’re confident that IQVIA, with its leading EQMS solutions, local domain expertise and support will enable us to manage ongoing quality processes, better assess potential risk, and drive continuous improvement and efficiencies, within our fast-growing global operations.”
The SmartSolveTM platform and EQMS suite are an example of the purpose-built solutions within the IQVIA Technologies Suite focused on meeting the needs of its life science customers working in a highly regulated industry in which the degree of quality and compliance of every internal process can have far-reaching implications for future growth.
For more information about IQVIA’s SmartSolve platform click here.
Medytox, Inc. is a publicly traded biopharmaceutical company focused on leveraging its proprietary technologies in the microbial toxin area to develop innovative biotech products to diagnose and treat diseases. Medytox, Inc. is the only biopharmaceutical company in the world to have three different types of botulinum toxin products (Neuronox, INNOTOX, Coretox), and INNOTOX is the only approved liquid toxin available anywhere in the world. All Medytox products have been developed by in-house R&D. Since the approval of Neuronox and INNOTOX, Medytox has continued its strong growth by maintaining a strong position in medical aesthetics as well as therapeutic indications associated with movement disorder. www.Medytox.com
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.